Market Overview - U.S. stock futures were higher, with Dow futures gaining over 100 points on Thursday [1] Company-Specific Movements - Satellogic Inc. (NASDAQ:SATL) shares fell 13.1% to $3.60 in pre-market trading following a proposed public offering [1] - American Battery Technology Company (NASDAQ:ABAT) shares dipped 23.9% to $6.81 after the DOE terminated its grant [3] - Hyperfine, Inc. (NASDAQ:HYPR) shares decreased 14.1% to $1.89 after reporting preliminary third-quarter revenue results below estimates and announcing a proposed public offering [3] - Omeros Corporation (NASDAQ:OMER) shares declined 9.2% to $9.45 after a significant 154% jump on Wednesday due to Novo Nordisk acquiring its global rights to Zaltenibart [3] - Hewlett Packard Enterprise Company (NYSE:HPE) tumbled 8.6% to $22.85 despite reporting record revenue driven by AI demand, as restructuring costs compressed profit margins [3] - NIO Inc. (NYSE:NIO) fell 8.5% to $6.24 in pre-market trading [3] - Inventiva S.A. (NASDAQ:IVA) declined 7.5% to $5.06 after a 10% gain on Wednesday [3] - Bitfarms Ltd. (NASDAQ:BITF) fell 4.6% to $6.17 after announcing a $300 million convertible senior notes offering [3] - Rigetti Computing, Inc. (NASDAQ:RGTI) shares fell 4.8% to $53.66 amid concerns over leadership commitment after the CEO sold all shares following an options exercise [3] - Datavault AI Inc. (NASDAQ:DVLT) slipped 4.8% to $2.00 in pre-market trading [3]

Market Overview - U.S. stock futures were higher, with Dow futures gaining over 100 points on Thursday [1] Company-Specific Movements - Satellogic Inc. (NASDAQ:SATL) shares fell 13.1% to $3.60 in pre-market trading following a proposed public offering [1] - American Battery Technology Company (NASDAQ:ABAT) shares dipped 23.9% to $6.81 after the DOE terminated a grant [3] - Hyperfine, Inc. (NASDAQ:HYPR) shares decreased 14.1% to $1.89 due to preliminary third-quarter revenue results falling below estimates and a proposed public offering [3] - Omeros Corporation (NASDAQ:OMER) shares declined 9.2% to $9.45 after a significant 154% increase the previous day following Novo Nordisk's acquisition of its global rights to Zaltenibart [3] - Hewlett Packard Enterprise Company (NYSE:HPE) tumbled 8.6% to $22.85 despite reporting record revenue driven by AI demand, as restructuring costs compressed profit margins [3] - NIO Inc. (NYSE:NIO) fell 8.5% to $6.24 in pre-market trading [3] - Inventiva S.A. (NASDAQ:IVA) declined 7.5% to $5.06 after a 10% gain the previous day [3] - Bitfarms Ltd. (NASDAQ:BITF) fell 4.6% to $6.17 after announcing a $300 million convertible senior notes offering [3] - Rigetti Computing, Inc. (NASDAQ:RGTI) shares fell 4.8% to $53.66 following CEO Subodh K. Kulkarni's sale of 1,000,000 shares, raising concerns about leadership commitment [3] - Datavault AI Inc. (NASDAQ:DVLT) slipped 4.8% to $2.00 in pre-market trading [3]

Core Viewpoint - Inventiva has filed a shelf registration statement with the SEC for a new At-The-Market (ATM) program, allowing the company to issue and sell up to $100 million in American Depositary Shares (ADS) to finance research and development, working capital, and general corporate purposes [1][2]. Group 1: Registration Statement and ATM Program - The registration statement includes a base prospectus and a sales agreement prospectus, enabling the company to sell ADSs at market prices, with a maximum dilution limit of 30% over a rolling 12-month period [1][3]. - The maximum number of underlying ordinary shares to be admitted to trading on Euronext Paris will represent less than 30% of the already admitted shares over a 12-month period [3][10]. - The sales agent, Piper Sandler, will facilitate the sale of ADSs, with prices varying based on market conditions, and the sales price will not be less than the volume-weighted average price of the company's shares [5][6]. Group 2: Use of Proceeds - The net proceeds from the sale of ADSs will be used for the research and development of lanifibranor, working capital needs, and general corporate purposes [2]. Group 3: Investor Eligibility and Trading - Purchases of ADSs under the ATM program are limited to specific categories of investors, including those regularly investing in the pharmaceutical and biotechnology sectors [4]. - The new ordinary shares will be traded on Euronext Paris, while the issued ADSs will be available on Nasdaq [8]. Group 4: Company Overview - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and is currently evaluating lanifibranor in a pivotal Phase 3 clinical trial [12].

Summary of Key Points Core Viewpoint - U.S. stock futures are slightly lower, with Nasdaq futures down approximately 0.1% on Thursday, indicating a cautious market sentiment [1]. Company-Specific Summaries Helen of Troy Ltd (NASDAQ:HELE) - Helen of Troy reported quarterly earnings of 59 cents per share, surpassing the analyst consensus estimate of 53 cents per share [1]. - The company achieved quarterly sales of $431.781 million, exceeding the analyst consensus estimate of $418.806 million [1]. - For FY2026, Helen of Troy projects adjusted EPS between $3.75 and $4.25, which is below market estimates of $4.58 [1]. - The company anticipates sales in the range of $1.739 billion to $1.780 billion, compared to market estimates of $1.750 billion [1]. - Shares of Helen of Troy fell 16.7% to $23.00 in pre-market trading following the earnings report [2]. Ferrari NV (NYSE:RACE) - Ferrari's shares decreased by 12.4% to $420.00 in pre-market trading after the release of its comprehensive 2030 strategic plan and updated near-term financial guidance [4]. Apogee Therapeutics, Inc. (NASDAQ:APGE) - Apogee Therapeutics' stock tumbled 9.6% to $42.70 in pre-market trading after announcing a $300 million underwritten public offering [4]. AZZ Inc (NYSE:AZZ) - AZZ Inc's shares declined by 9.4% to $96.01 in pre-market trading following weak second-quarter results [4]. Plug Power Inc. (NASDAQ:PLUG) - Plug Power's stock fell 7.8% to $3.37 in pre-market trading after a decline of more than 5% on Wednesday, despite raising $370 million from the immediate exercise of 185.4 million warrants at $2 per share [4]. Other Notable Stocks - Inventiva (NYSE:IVA) shares fell 6.3% to $5.02 in pre-market trading [4]. - NextNRG Inc (NASDAQ:NXXT) saw a decline of 5.8% to $2.59 in pre-market trading [4].

Group 1: Helen of Troy Ltd - Helen of Troy reported quarterly earnings of 59 cents per share, beating the analyst consensus estimate of 53 cents per share [1] - The company reported quarterly sales of $431.781 million, exceeding the analyst consensus estimate of $418.806 million [1] - For FY2026, Helen of Troy expects adjusted EPS of $3.75-$4.25, lower than market estimates of $4.58, and sales of $1.739 billion-$1.780 billion, compared to market estimates of $1.750 billion [1] Group 2: Stock Movements - Helen of Troy shares fell 16.7% to $23.00 in pre-market trading following the earnings report [2] - Ferrari NV shares decreased by 12.4% to $420.00 after releasing its 2030 strategic plan and updated financial guidance [4] - Apogee Therapeutics, Inc. shares tumbled 9.6% to $42.70 after announcing a $300 million public offering [4] - AZZ Inc shares declined 9.4% to $96.01 following weak second-quarter results [4] - Plug Power Inc shares fell 7.8% to $3.37 after raising $370 million from the exercise of warrants [4] - Inventiva shares decreased by 6.3% to $5.02 in pre-market trading [4] - NextNRG Inc shares fell 5.8% to $2.59 in pre-market trading [4]

Core Points - The article emphasizes the importance of enabling Javascript and cookies in browsers to prevent access issues [1] Group 1 - The article suggests that users may face blocks if they have an ad-blocker enabled, indicating a need to disable it for proper access [1]

Core Insights - The company is introducing lanifibranor as a promising oral therapy for patients with MASH [1][2] - A significant funding round of over $400 million was completed approximately a year ago, enhancing the company's position for the global Phase III NATiV3 trial [2][3] - The company successfully accelerated enrollment for the trial, resulting in over-enrollment, which was announced in April of this year [3]

Summary of Inventiva Investor Day - October 08, 2025 Company Overview - **Company**: Inventiva (NasdaqGM:IVA) - **Focus**: Development of lanifibranor, an oral therapy for MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease) [1][2] Key Points and Arguments Management Changes - Recently raised over $400 million through a PIPE, enhancing the company's position for the global Phase 3 NATIVE 3 trial [2] - New Chief Medical Officer Jason Campagna and new CEO Andrew Ovenshain have joined the management team, bringing extensive experience in the biopharma sector [3][4] Market Opportunity - MASH is a progressive liver disease, underdiagnosed with only 10% of the 18 million patients in the U.S. diagnosed [9] - There are approximately 367,000 under-treated patients in the U.S., a 70% increase from four years ago, indicating a growing market [10] - Despite existing treatments, 90% of physicians believe there is a need for more effective products targeting liver diseases [10] Lanifibranor's Unique Positioning - Lanifibranor is a pan-PPAR agonist designed specifically for MASH, showing an 18% improvement in fibrosis in just six months during Phase 2b trials [11] - The therapy is an oral once-a-day monotherapy with a manageable safety profile, addressing both liver fibrosis and cardiovascular markers [11] Clinical Development and Future Milestones - The company aims to deliver top-line results from the NATIVE 3 trial in the second half of 2026 and plans to launch the therapy in 2028 [13] - The NATIVE 3 trial is fully enrolled, focusing on non-cirrhotic F2/F3 patients, with a primary endpoint of MASH resolution and fibrosis improvement [42] Additional Important Insights Mechanism of Action - Lanifibranor targets multiple pathways involved in MASH progression, including inflammation and fibrosis, through its action on PPAR receptors [20][21] - The drug has shown improvements in metabolic parameters, including reductions in fasting glucose and triglycerides, and increases in HDL cholesterol [24][25] Real-World Application and Treatment Landscape - The treatment landscape for MASH includes lifestyle modifications, GLP-1 agonists, and potential combination therapies with lanifibranor [55][63] - The real-world application of therapies is complex, with many patients already on GLP-1s and requiring careful management of their treatment regimens [62][64] Challenges and Considerations - The under-treatment and over-treatment of patients based on clinical risk factors highlight the need for better diagnostic and treatment strategies [65] - The integration of new therapies like lanifibranor into existing treatment protocols will require careful consideration of patient profiles and potential synergies with other medications [27][63] This summary encapsulates the key points discussed during the Inventiva Investor Day, focusing on the company's strategic direction, market potential, and the clinical development of lanifibranor as a treatment for MASH.

Lanifibranor's Potential and Mechanism - Lanifibranor is a promising oral small molecule designed to treat MASH by targeting intrahepatic fibrosis progression and extrahepatic manifestations, delivering anti-inflammatory & metabolic benefits[13] - Lanifibranor is a differentiated pan-PPAR agonist with moderate and well-balanced activity on the three PPAR isoforms[34] - Phase 2b data showed an 18% improvement in fibrosis with no worsening of MASH vs placebo at 6 months (42% vs 24%, p=001) and improved cardiovascular, glycemic, and metabolic markers[14] - Lanifibranor observed to induce a decrease in key serum biomarkers consistent with histologic endpoints, with a 139% decrease in Pro-C3 (p=0005) and a 411% decrease in CK18-M30 (p<0001) compared to placebo[81] Market and Clinical Trial Landscape - The US has approximately 19 million diagnosed MASH patients[9] - Analysis shows significantly more than ~315K MASH patients are under treater care[10] - 85% of specialists in the US described the greatest unmet needs as lack of effective, liver directed therapies[12] - In the Phase 2b NATIVE trial, 24% of patients on lanifibranor 1200mg achieved resolution of MASH and improvement of fibrosis, compared to 3% on placebo[76] - NATiV3 is fully recruited with 1009 patients in the main cohort and 410 in the exploratory cohort[95] Inventiva's Strategy and Timeline - Inventiva raised $411 million in a successful PIPE financing in October 2024[7] - Inventiva aims to re-define MASH treatment with lanifibranor, with targeted launch in 2028[16, 17] - Topline results for NATiV3 are expected in H2 2026[7, 17]

Core Insights - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and announced four abstract presentations at the upcoming AASLD The Liver Meeting® 2025 [1][6] Presentation Details - The first abstract compares digital images versus glass slides for histopathological evaluation of liver biopsy samples in the NATiV3 study, scheduled for presentation on November 8, 2025 [2][3] - The second abstract discusses continuous digital pathology scoring revealing fibrosis reversal and therapeutic benefits of lanifibranor, with a presentation date of November 9, 2025 [2] - The third abstract highlights high-resolution digital pathology demonstrating antifibrotic and anti-inflammatory effects of lanifibranor in TAA-induced cirrhotic rodent models, also on November 9, 2025 [2] - The fourth abstract combines digital pathology and biomarkers to quantify fibrosis and treatment response to lanifibranor in a TAA-induced cirrhosis model, presented on November 9, 2025 [2] About Lanifibranor - Lanifibranor is Inventiva's lead product candidate, an orally available small molecule that activates all three PPAR isoforms, inducing anti-fibrotic and anti-inflammatory effects [5][6] - It is the only pan-PPAR agonist in clinical development for MASH, with the FDA granting Breakthrough Therapy and Fast Track designations [5] Company Overview - Inventiva is a public company listed on Euronext Paris and NASDAQ, focusing on the research and development of oral small molecule therapies for MASH [6][7]